Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million2026 total operating expenses expected in the range of ...

Pancreatic ductal adenocarcinoma (PDAC) is both the most common and the deadliest type of pancreatic cancer. Most treatment ...

Gene-editing technologies show great promise for medical treatments and research, with the potential to cure thousands of ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...